Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab

Campani C, Bamba-Funck J, Campion B, Sidali S, Blaise L, Ganne-Carrié N, Demory A, Sutter O, Larrey E, Evain M, Ghannouchi H, Wagner M, Marra F, Sutton A, Allaire M, Nault JC. Liver Int. 2023 Mar;43(3):708-717. doi: 10.1111/liv.15487. Epub 2022 Dec 14. Background: The combination of atezolizumab and bevacizumab (AtezoBev) is the current first-line treatment …

Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab Read More »

Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002-2022)

Sidali S, Sritharan N, Campani C, Gregory J, Durand F, Ganne-Carrié N, Ronot M, Lévy V, Nault JC. JHEP Rep. 2023 Apr 7;5(7):100755. doi: 10.1016/j.jhepr.2023.100755. Background & aims: The fragility index (FI), i.e., theminimum number of best survivors reassigned to the control group required to revert the statistically significant result of a clinical trial to …

Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002-2022) Read More »

Benign liver tumours: understanding molecular physiology to adapt clinical management

Nault JC, Paradis V, Ronot M, Zucman-Rossi J. Abstract Improvements in understanding the pathophysiology of the different benign liver nodules have refined their nosological classification. New criteria have been identified using imaging, histology and molecular analyses for a precise diagnosis of these tumours. Improvement in the classification of liver tumours provides a more accurate prediction …

Benign liver tumours: understanding molecular physiology to adapt clinical management Read More »

Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation

Demory A, Péron JM, Calderaro J, Selves J, Mokrane FZ, Amaddeo G, Paradis V, Ziol M, Sutter O, Blaise L, Ganne-Carrié N, Vilgrain V, Cauchy F, Zucman-Rossi J, Ronot M, Nault JC Background and aims: The natural history of hepatocellular adenomas (HCAs) remains to be better described, especially in nonresected patients. We aim to identify the predictive …

Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation Read More »

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, Parikh ND, Marrero JA. Abstract Background & aims: There is controversy regarding the overall value of hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis given the lack of data from randomized-controlled trials. To address this issue, we …

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis Read More »

ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts

Ollivier-Hourmand I, Repesse Y, Nahon P, Chaffaut C, Dao T, Nguyen TTN, Marcellin P, Roulot D, De Ledinghen V, Pol S, Guyader D, Archambeaud I, Zoulim F, Oberti F, Tran A, Bronowicki JP, D’Alteroche L, Ouzan D, Peron JM, Zarski JP, Bourliere M, Larrey D, Louvet A, Cales P, Abergel A, Mathurin P, Mallat A, …

ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts Read More »

Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease

Dana J, Venkatasamy A, Saviano A, Lupberger J, Hoshida Y, Vilgrain V, Nahon P, Reinhold C, Gallix B, Baumert TF. Abstract Chronic liver diseases, resulting from chronic injuries of various causes, lead to cirrhosis with life-threatening complications including liver failure, portal hypertension, hepatocellular carcinoma. A key unmet medical need is robust non-invasive biomarkers to predict patient …

Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease Read More »

Clinical, histological and molecular profiling of different stages of alcohol-related liver disease

Ventura-Cots M, Argemi J, Jones PD, Lackner C, El Hag M, Abraldes JG, Alvarado E, Clemente A, Ravi S, Alves A, Alboraie M, Altamirano J, Barace S, Bosques F, Brown R, Caballeria J, Cabezas J, Carvalhana S, Cortez-Pinto H, Costa A, Degré D, Fernandez-Carrillo C, Ganne-Carrie N, Garcia-Tsao G, Genesca J, Koskinas J, Lanthier N, Louvet …

Clinical, histological and molecular profiling of different stages of alcohol-related liver disease Read More »

Implementing advanced practice nursing in France: A country-wide survey 2 years after its introduction

Devictor J, Burnet E, Henriot T, Leclercq A, Ganne-Carrie N, Kilpatrick K, Jovic L Abstract Objectives: To examine the characteristics of the first Advanced Practice Nurses in France and to compare the French model to international standards. Background: Common barriers and facilitators to their integration in healthcare provision have been identified internationally. In France, the legislative framework was …

Implementing advanced practice nursing in France: A country-wide survey 2 years after its introduction Read More »